LeMaitre Vascular Inc (NASDAQ:LMAT) Expected to Post Quarterly Sales of $30.49 Million
Brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to post sales of $30.49 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for LeMaitre Vascular’s earnings. The highest sales estimate is $30.51 million and the lowest is $30.47 million. LeMaitre Vascular posted sales of $28.39 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.4%. The business is expected to announce its next quarterly earnings report on Tuesday, February 18th.
On average, analysts expect that LeMaitre Vascular will report full year sales of $117.57 million for the current year, with estimates ranging from $117.53 million to $117.60 million. For the next fiscal year, analysts forecast that the business will post sales of $129.66 million, with estimates ranging from $128.70 million to $130.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, October 23rd. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.04. The company had revenue of $29.10 million for the quarter, compared to analyst estimates of $28.15 million. LeMaitre Vascular had a net margin of 16.76% and a return on equity of 13.38%. The firm’s revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share.
In related news, CFO Joseph P. Pellegrino, Jr. sold 64,792 shares of LeMaitre Vascular stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $35.88, for a total transaction of $2,324,736.96. Following the completion of the sale, the chief financial officer now owns 211,878 shares in the company, valued at approximately $7,602,182.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 7,068 shares of LeMaitre Vascular stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $37.17, for a total value of $262,717.56. Following the sale, the chief executive officer now owns 3,089,687 shares of the company’s stock, valued at approximately $114,843,665.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 237,435 shares of company stock valued at $8,408,790. 19.60% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of LMAT. Russell Investments Group Ltd. boosted its stake in LeMaitre Vascular by 92.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock worth $12,333,000 after buying an additional 173,214 shares during the last quarter. Copeland Capital Management LLC boosted its stake in LeMaitre Vascular by 38.7% in the 3rd quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock worth $18,327,000 after buying an additional 149,642 shares during the last quarter. GW&K Investment Management LLC acquired a new stake in LeMaitre Vascular in the 2nd quarter worth about $3,734,000. Morgan Stanley boosted its stake in LeMaitre Vascular by 151.7% in the 2nd quarter. Morgan Stanley now owns 202,672 shares of the medical instruments supplier’s stock worth $5,671,000 after buying an additional 122,152 shares during the last quarter. Finally, Nuveen Asset Management LLC acquired a new stake in LeMaitre Vascular in the 2nd quarter worth about $2,612,000. 79.17% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:LMAT opened at $35.37 on Tuesday. The stock has a fifty day moving average price of $34.63 and a two-hundred day moving average price of $31.34. The stock has a market capitalization of $711.09 million, a price-to-earnings ratio of 42.11, a PEG ratio of 4.02 and a beta of 1.21. LeMaitre Vascular has a 1 year low of $21.79 and a 1 year high of $37.35.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Wednesday, November 20th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Tuesday, November 19th. LeMaitre Vascular’s dividend payout ratio is presently 40.48%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.